Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Pacific Edge Limited ( (PFGTF) ) is now available.
Pacific Edge Limited has appointed James Vaughn as the new Chief Commercial Officer to enhance the global adoption of its Cxbladder diagnostic tests, following the inclusion of Cxbladder Triage in the American Urological Association guidelines. Vaughn’s extensive experience in the pharmaceutical and diagnostics sectors, including his success at Genomic Health, positions him to drive growth and market penetration for Pacific Edge, with a focus on increasing sales and improving reimbursement rates for its non-invasive bladder cancer tests.
More about Pacific Edge Limited
Pacific Edge Limited is a global cancer diagnostics company specializing in the development and commercialization of bladder cancer diagnostic and prognostic tests. The company focuses on innovative solutions in the medical diagnostics industry, particularly targeting bladder cancer.
See more data about PFGTF stock on TipRanks’ Stock Analysis page.